GT Biopharma, Inc. (GTBP) Financial Statements
GT Biopharma, Inc. (GTBP) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$4.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$12.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GTBPGT Biopharma, Inc.Follow GTBP — free
—
Price chart with a free account
- Market cap
- 9.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | -0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | |
| Research & development | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 1.0 | 1.1 | 9.1 | 1.7 | 0.5 | 9.6 | 8.8 | 6.5 | 5.8 | 3.5 | 3.5 | |
| Operating income | -3.9 | -3.5 | -0.8 | -2.4 | -8.9 | -9.4 | -135.6 | -250.1 | 16.1 | -6.8 | -57.5 | -21.3 | -13.6 | -14.4 | -12.4 | -16.3 | |
| Pre-tax income | -3.7 | -5.3 | -0.6 | -23.5 | -21.5 | 9.8 | -144.2 | -259.2 | -38.6 | -28.3 | -58.0 | -20.9 | -7.6 | -13.2 | -28.4 | -4.8 | |
| Income tax | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | |
| Net income | -3.7 | -5.2 | -0.5 | -23.5 | -21.5 | 9.8 | -144.2 | -259.2 | -38.6 | -28.3 | -58.0 | -20.9 | -7.6 | -13.2 | -28.4 | -4.8 | |
| Diluted EPS ($) | -0.02 | -0.01 | -0.01 | -0.04 | -8.96 | 0.86 | -215.00 | -129.00 | -0.01 | -6.45 | -2.06 | -19.66 | -5.64 | -6.94 | -6.68 | -8.88 | |
| Diluted shares (mn) | — | — | — | — | — | 0.1 | 0.7 | 2.0 | 3.4 | 4.4 | — | 1.1 | 1.3 | 1.9 | 5.5 | — |
USD millions · SEC XBRL
GT Biopharma, Inc. — questions
- What is GT Biopharma, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is GT Biopharma, Inc.'s net income?
- -$4.8M over the twelve months to 2026-06-30.
- What is GT Biopharma, Inc.'s free cash flow?
- -$12.9M over the twelve months to 2026-06-30.
- What are GT Biopharma, Inc.'s diluted earnings per share?
- $-8.88 over the twelve months to 2026-06-30.
Every figure on this page comes from GT Biopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.